Looking at the safety and efficacy of a once daily inhaled triple medication therapy for patients with COPD. The triple combination will be compared to the current market available dual combiniation therapies. Patients who qualify will be assigned to either the investigational product or one of the dual therapies. They will be followed for 52 weeks and have approximately 7 clinic visits. Patients will be asked to keep a daily diary of their respiratory symptoms on a provided hand-held device.
Who may be Eligible
Patients 40 years and older with a diagnosis of COPD
Have a history of tobacco use
Have a history of COPD exacerbations
Do not have a current diagnosis of asthma